by John.norman | Jun 20, 2022 | News
Optibrium receives further investment from Kester Capital Second round of funding from existing investors will further drive company expansion and commercial growth of its AI-enabled drug discovery technology. CAMBRIDGE, UK, 21 June 2022 – Optibrium™, a developer of...
by John.norman | Jun 14, 2022 | News
Optimising Operations & Processes in Biotech Labs Recent developments in computational tools and how these can solve operational challenges in biotech labs. Interview published by Lab Manager: – Biotechnology labs face many challenges, such as operations and...
by John.norman | Jun 8, 2022 | News
Optibrium expands UK head office with new facilities on Cambridge Innovation Park Investment in new headquarters forms part of ongoing company growth plans. The new facility supports the continued success of Optibrium’s drug discovery technologies and...
by John.norman | Apr 13, 2022 | News
Prediction of In Vivo Pharmacokinetic Parameters and Time− Exposure Curves in Rats Using Machine Learning from the Chemical Structure Published in Molecular Pharmaceutics, the paper describes the particularly challenging use of Alchemite to predict in vivo...
by John.norman | Apr 6, 2022 | News
Early Development Medicinal Chemistry: Utilizing Data and Artificial Intelligence In this Pharmaceutical Technology article, Meg Rivers interviews Optibrium’s Chase Smith and Verseon’s Kevin Short to discuss what data to consider when selecting a...
by Thanos Panagiotidis | Mar 1, 2022 | News
Optibrium Adds Augmented Intelligence for Compound Design to its StarDrop Small Molecule Drug Discovery Software New Inspyra™ module combines chemists’ expertise with exploratory capabilities of automated compound design. Inspyra™ provides drug designers direct...
Recent Comments